BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012;30:2601-8. [PMID: 22711854 DOI: 10.1200/JCO.2011.37.2482] [Cited by in Crossref: 276] [Cited by in F6Publishing: 157] [Article Influence: 27.6] [Reference Citation Analysis]
Number Citing Articles
1 Li A, Keck JM, Parmar S, Patterson J, Labrie M, Creason AL, Johnson BE, Downey M, Thomas G, Beadling C, Heiser LM, Kolodzie A, Guimaraes AR, Corless CL, Gray JW, Mills GB, Bergan RC, Mitri ZI. Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. NPJ Precis Oncol 2021;5:28. [PMID: 33772089 DOI: 10.1038/s41698-021-00165-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Shen Q, Sahin AA, Hess KR, Suki D, Aldape KD, Sawaya R, Ibrahim NK. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist 2015;20:466-73. [PMID: 25802405 DOI: 10.1634/theoncologist.2014-0107] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
3 Ullah I, Karthik GM, Alkodsi A, Kjällquist U, Stålhammar G, Lövrot J, Martinez NF, Lagergren J, Hautaniemi S, Hartman J, Bergh J. Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes. J Clin Invest 2018;128:1355-70. [PMID: 29480816 DOI: 10.1172/JCI96149] [Cited by in Crossref: 69] [Cited by in F6Publishing: 43] [Article Influence: 17.3] [Reference Citation Analysis]
4 Feng Z, Wen H, Ju X, Bi R, Chen X, Yang W, Wu X. Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers. Oncotarget 2017;8:32848-55. [PMID: 28416763 DOI: 10.18632/oncotarget.15858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
5 Boolbol SK, Harshan M, Chadha M, Kirstein L, Cohen JM, Klein P, Anderson J, Davison D, Jakubowski DM, Baehner FL, Malamud S. Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence Score® test. Breast Cancer Res Treat 2019;177:611-8. [PMID: 31302854 DOI: 10.1007/s10549-019-05346-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ding J, Hu P, Chen J, Wu X, Cao Y. The importance of tissue confirmation of metastatic disease in patients with breast cancer: lesson from a brain metastasis case. Oncoscience 2016;3:268-74. [PMID: 28050577 DOI: 10.18632/oncoscience.320] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Tachtsidis A, McInnes LM, Jacobsen N, Thompson EW, Saunders CM. Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells. Clin Exp Metastasis 2016;33:521-50. [PMID: 27189371 DOI: 10.1007/s10585-016-9796-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
8 Shin HC, Han W, Moon HG, Park IA, Noh DY. Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis. J Breast Cancer 2016;19:268-74. [PMID: 27721876 DOI: 10.4048/jbc.2016.19.3.268] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
9 Qu Q, Zong Y, Fei XC, Chen XS, Xu C, Lou GY, Shen KW. The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer. World J Surg Oncol 2014;12:93. [PMID: 24721777 DOI: 10.1186/1477-7819-12-93] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
10 Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013;274:113-126. [PMID: 23844915 DOI: 10.1111/joim.12084] [Cited by in Crossref: 305] [Cited by in F6Publishing: 297] [Article Influence: 33.9] [Reference Citation Analysis]
11 Aurilio G, Monfardini L, Rizzo S, Sciandivasci A, Preda L, Bagnardi V, Disalvatore D, Pruneri G, Munzone E, Della Vigna P, Renne G, Bellomi M, Curigliano G, Goldhirsch A, Nolè F. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. Acta Oncol 2013;52:1649-56. [PMID: 23327413 DOI: 10.3109/0284186X.2012.754990] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
12 Fadoukhair Z, Zardavas D, Chad MA, Goulioti T, Aftimos P, Piccart M. Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs. Oncogene 2016;35:1743-9. [PMID: 26119941 DOI: 10.1038/onc.2015.249] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
13 Pizzuti L, Barba M, Mazzotta M, Krasniqi E, Maugeri-Saccà M, Gamucci T, Berardi R, Livi L, Ficorella C, Natoli C, Cortesi E, Generali D, La Verde N, Cassano A, Bria E, Moscetti L, Michelotti A, Adamo V, Zamagni C, Tonini G, Sergi D, Marinelli D, Paoletti G, Tomao S, Botticelli A, Marchetti P, Tinari N, Grassadonia A, Valerio MR, Mirabelli R, Fabbri MA, D'Ostilio N, Veltri E, Corsi D, Garrone O, Paris I, Sarobba G, Meattini I, Pistelli M, Giotta F, Lorusso V, Garufi C, Russo A, Cazzaniga M, Del Medico P, Roselli M, Vaccaro A, Perracchio L, di Benedetto A, Daralioti T, Sperduti I, De Maria R, Di Leo A, Sanguineti G, Ciliberto G, Vici P. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. Sci Rep 2021;11:13770. [PMID: 34215766 DOI: 10.1038/s41598-021-92774-z] [Reference Citation Analysis]
14 Kulka J, Székely B, Lukács LV, Kiss O, Tőkés AM, Vincze E, Turányi E, Fillinger J, Hanzély Z, Arató G, Szendrői M, Győrffy B, Szász AM. Comparison of Predictive Immunohistochemical Marker Expression of Primary Breast Cancer and Paired Distant Metastasis using Surgical Material: A Practice-Based Study. J Histochem Cytochem 2016;64:256-67. [PMID: 27029768 DOI: 10.1369/0022155416639013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
15 Tobin NP, Lundberg A, Lindström LS, Harrell JC, Foukakis T, Carlsson L, Einbeigi Z, Linderholm BK, Loman N, Malmberg M, Fernö M, Czene K, Perou CM, Bergh J, Hatschek T; TEX Trialists Group. PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. Clin Cancer Res 2017;23:7225-31. [PMID: 28972041 DOI: 10.1158/1078-0432.CCR-17-2301] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
16 Xie Y, Du X, Zhao Y, Gong C, Hu S, You S, Song S, Hu X, Yang Z, Wang B. Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by 18F-FES PET. Cancers 2022;14:3531. [DOI: 10.3390/cancers14143531] [Reference Citation Analysis]
17 Callens C, Driouch K, Boulai A, Tariq Z, Comte A, Berger F, Belin L, Bièche I, Servois V, Legoix P, Bernard V, Baulande S, Chemlali W, Bidard FC, Fourchotte V, Salomon AV, Brain E, Lidereau R, Bachelot T, Saghatchian M, Campone M, Giacchetti S, Zafrani BS, Cottu P. Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study. Genome Med 2021;13:44. [PMID: 33722295 DOI: 10.1186/s13073-021-00862-6] [Reference Citation Analysis]
18 Ignatiadis M, Sotiriou C. Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol. 2013;10:494-506. [PMID: 23881035 DOI: 10.1038/nrclinonc.2013.124] [Cited by in Crossref: 106] [Cited by in F6Publishing: 99] [Article Influence: 11.8] [Reference Citation Analysis]
19 Tangen IL, Onyango TB, Kopperud R, Berg A, Halle MK, Øyan AM, Werner HM, Trovik J, Kalland KH, Salvesen HB, Krakstad C. Androgen receptor as potential therapeutic target in metastatic endometrial cancer. Oncotarget 2016;7:49289-98. [PMID: 27384477 DOI: 10.18632/oncotarget.10334] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
20 Zheng Y, Yang X. Application and prospect of single-cell sequencing in cancer metastasis. Future Oncol 2022;18:2723-36. [PMID: 35686493 DOI: 10.2217/fon-2022-0156] [Reference Citation Analysis]
21 Chen SC, Yu CC, Chang HK, Lin YC, Lo YF, Shen SC, Kuo WL, Tsai HP, Chou HH, Chu CH, Shen WC, Wu RC, Ueng SH, Huang YT. Discrepancy of Breast and Axillary Pathologic Complete Response and Outcomes in Different Subtypes of Node-positive Breast Cancer after Neoadjuvant Chemotherapy. J Cancer 2021;12:5365-74. [PMID: 34335953 DOI: 10.7150/jca.62830] [Reference Citation Analysis]
22 Tam AL, Lim HJ, Wistuba II, Tamrazi A, Kuo MD, Ziv E, Wong S, Shih AJ, Webster RJ 3rd, Fischer GS, Nagrath S, Davis SE, White SB, Ahrar K. Image-Guided Biopsy in the Era of Personalized Cancer Care: Proceedings from the Society of Interventional Radiology Research Consensus Panel. J Vasc Interv Radiol 2016;27:8-19. [PMID: 26626860 DOI: 10.1016/j.jvir.2015.10.019] [Cited by in Crossref: 48] [Cited by in F6Publishing: 34] [Article Influence: 6.9] [Reference Citation Analysis]
23 Bensch F, Brouwers AH, Lub-de Hooge MN, de Jong JR, van der Vegt B, Sleijfer S, de Vries EGE, Schröder CP. 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up. Eur J Nucl Med Mol Imaging 2018;45:2300-6. [PMID: 30058029 DOI: 10.1007/s00259-018-4099-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
24 Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL, Mittendorf EA, Nanda R, Page DB, Rugo HS, Rubin KM, Soliman H, Spears PA, Tolaney SM, Litton JK. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer 2021;9:e002597. [PMID: 34389617 DOI: 10.1136/jitc-2021-002597] [Reference Citation Analysis]
25 Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D, Salgado R, Aftimos P, Saini KS, Sotiriou C, Campbell P, Dinh P, von Minckwitz G, Gelber RD, Dowsett M, Di Leo A, Cameron D, Baselga J, Gnant M, Goldhirsch A, Norton L, Piccart M. The AURORA initiative for metastatic breast cancer. Br J Cancer 2014;111:1881-7. [PMID: 25225904 DOI: 10.1038/bjc.2014.341] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 7.5] [Reference Citation Analysis]
26 Bergh J, Pritchard KI, Cameron D. Sisyphean Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies. J Clin Oncol 2016;34:895-7. [PMID: 26786914 DOI: 10.1200/JCO.2015.65.2255] [Reference Citation Analysis]
27 O’brien SR, Edmonds CE, Katz D, Mankoff DA, Pantel AR. 18F-Fluoroestradiol (FES) PET/CT: review of current practice and future directions. Clin Transl Imaging. [DOI: 10.1007/s40336-022-00494-9] [Reference Citation Analysis]
28 Kutasovic JR, McCart Reed AE, Sokolova A, Lakhani SR, Simpson PT. Morphologic and Genomic Heterogeneity in the Evolution and Progression of Breast Cancer. Cancers (Basel) 2020;12:E848. [PMID: 32244556 DOI: 10.3390/cancers12040848] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
29 Stefanovic S, Deutsch TM, Riethdorf S, Fischer C, Hartkopf A, Sinn P, Feisst M, Pantel K, Golatta M, Brucker SY, Sütterlin M, Schneeweiss A, Wallwiener M. The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer. Int J Mol Sci 2020;21:E2161. [PMID: 32245182 DOI: 10.3390/ijms21062161] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Grüntkemeier L, Khurana A, Bischoff FZ, Hoffmann O, Kimmig R, Moore M, Cotter P, Kasimir-Bauer S. Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™-HER2-FISH workflow. Breast Cancer 2022. [PMID: 35025065 DOI: 10.1007/s12282-022-01330-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Jamshidi N, Jonasch E, Zapala M, Korn RL, Brooks JD, Ljungberg B, Kuo MD. The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. Eur Radiol 2016;26:2798-807. [PMID: 26560727 DOI: 10.1007/s00330-015-4082-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
32 Moon H, Noh WC, Kim HA, Kim EK, Park KW, Lee SS, Choi JH, Han KW, Byun BH, Lim I, Kim BI, Choi CW, Lim SM. The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase (18)F-FDG PET/CT. Nucl Med Mol Imaging 2016;50:246-54. [PMID: 27540429 DOI: 10.1007/s13139-016-0412-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
33 Paquette M, Lavallée É, Phoenix S, Ouellet R, Senta H, van Lier JE, Guérin B, Lecomte R, Turcotte ÉE. Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor-Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial. J Nucl Med 2018;59:197-203. [PMID: 28798032 DOI: 10.2967/jnumed.117.194654] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
34 Zattarin E, Leporati R, Ligorio F, Lobefaro R, Vingiani A, Pruneri G, Vernieri C. Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications. Cells 2020;9:E2644. [PMID: 33316954 DOI: 10.3390/cells9122644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Almstedt K, Schmidt M. Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. Breast Care (Basel). 2015;10:168-172. [PMID: 26557821 DOI: 10.1159/000405017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
36 Marino N, Woditschka S, Reed LT, Nakayama J, Mayer M, Wetzel M, Steeg PS. Breast cancer metastasis: issues for the personalization of its prevention and treatment. Am J Pathol 2013;183:1084-95. [PMID: 23895915 DOI: 10.1016/j.ajpath.2013.06.012] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
37 Guan X, Ma F, Liu S, Wu S, Xiao R, Yuan L, Sun X, Yi Z, Yang H, Xu B. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells. Oncotarget. 2016;7:65993-66002. [PMID: 27602758 DOI: 10.18632/oncotarget.11787] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
38 Jung J, Lee SH, Park M, Youn JH, Shin SH, Gwak HS, Yoo H. Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis. J Neurooncol 2018;137:295-302. [PMID: 29260362 DOI: 10.1007/s11060-017-2717-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
39 Sandberg D, Tolmachev V, Velikyan I, Olofsson H, Wennborg A, Feldwisch J, Carlsson J, Lindman H, Sörensen J. Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT. Eur J Nucl Med Mol Imaging 2017;44:1337-46. [PMID: 28261749 DOI: 10.1007/s00259-017-3650-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
40 Collisson EA, Cho RJ, Gray JW. What are we learning from the cancer genome? Nat Rev Clin Oncol 2012;9:621-30. [PMID: 22965149 DOI: 10.1038/nrclinonc.2012.159] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
41 Shi YJ, Tsang JY, Ni YB, Tse GM. Intratumoral Heterogeneity in Breast Cancer: A Comparison of Primary and Metastatic Breast Cancers. Oncologist 2017;22:487-90. [PMID: 28341760 DOI: 10.1634/theoncologist.2016-0352] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
42 He W, Eriksson L, Törnberg S, Strand F, Hall P, Czene K. Discontinuation of adjuvant hormone therapy among breast cancer patients not previously attending mammography screening. BMC Med 2019;17:24. [PMID: 30700300 DOI: 10.1186/s12916-019-1252-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
43 Paoletti C, Muñiz MC, Thomas DG, Griffith KA, Kidwell KM, Tokudome N, Brown ME, Aung K, Miller MC, Blossom DL, Schott AF, Henry NL, Rae JM, Connelly MC, Chianese DA, Hayes DF. Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer. Clin Cancer Res 2015;21:2487-98. [PMID: 25381338 DOI: 10.1158/1078-0432.CCR-14-1913] [Cited by in Crossref: 84] [Cited by in F6Publishing: 40] [Article Influence: 10.5] [Reference Citation Analysis]
44 Lee MY, Chang WJ, Kim HS, Lee JY, Lim SH, Lee JE, Kim SW, Nam SJ, Ahn JS, Im YH, Park YH. Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series. PLoS One 2016;11:e0163254. [PMID: 27648567 DOI: 10.1371/journal.pone.0163254] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
45 Kurbasic E, Sjöström M, Krogh M, Folkesson E, Grabau D, Hansson K, Rydén L, Waldemarson S, James P, Niméus E. Changes in glycoprotein expression between primary breast tumour and synchronous lymph node metastases or asynchronous distant metastases. Clin Proteomics 2015;12:13. [PMID: 25991917 DOI: 10.1186/s12014-015-9084-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
46 Foukakis T, Lövrot J, Sandqvist P, Xie H, Lindström LS, Giorgetti C, Jacobsson H, Hedayati E, Bergh J. Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer. Mol Oncol 2015;9:1384-91. [PMID: 25888067 DOI: 10.1016/j.molonc.2015.03.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
47 Dehdashti F, Wu N, Bose R, Naughton MJ, Ma CX, Marquez-Nostra BV, Diebolder P, Mpoy C, Rogers BE, Lapi SE, Laforest R, Siegel BA. Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. Breast Cancer Res Treat 2018;169:523-30. [PMID: 29442264 DOI: 10.1007/s10549-018-4696-z] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
48 Awada A, Gligorov J, Jerusalem G, Preusser M, Singer C, Zielinski C. CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open-Cancer Horizons pro and con discussion. ESMO Open 2019;4:e000565. [PMID: 31798979 DOI: 10.1136/esmoopen-2019-000565] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
49 Mortimer JE, Bading JR, Colcher DM, Conti PS, Frankel PH, Carroll MI, Tong S, Poku E, Miles JK, Shively JE, Raubitschek AA. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET. J Nucl Med 2014;55:23-9. [PMID: 24337604 DOI: 10.2967/jnumed.113.122630] [Cited by in Crossref: 94] [Cited by in F6Publishing: 80] [Article Influence: 10.4] [Reference Citation Analysis]
50 D'Amico S, Krasnowska EK, Manni I, Toietta G, Baldari S, Piaggio G, Ranalli M, Gambacurta A, Vernieri C, Di Giacinto F, Bernassola F, de Braud F, Lucibello M. DHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines. Cells 2020;9:E1260. [PMID: 32438775 DOI: 10.3390/cells9051260] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
51 Magbanua MJM, Rugo HS, Hauranieh L, Roy R, Scott JH, Lee JC, Hsiao F, Sosa EV, Van't Veer L, Esserman LJ, Park JW. Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer. NPJ Breast Cancer 2018;4:31. [PMID: 30211312 DOI: 10.1038/s41523-018-0083-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
52 Duchnowska R, Wysocki PJ, Korski K, Czartoryska-Arłukowicz B, Niwińska A, Orlikowska M, Radecka B, Studziński M, Demlova R, Ziółkowska B, Merdalska M, Hajac Ł, Myśliwiec P, Zuziak D, Dębska-Szmich S, Lang I, Foszczyńska-Kłoda M, Karczmarek-Borowska B, Żawrocki A, Kowalczyk A, Biernat W, Jassem J; Central and East European Oncology Group (CEEOG). Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients. Oncotarget 2016;7:550-64. [PMID: 26623720 DOI: 10.18632/oncotarget.6375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
53 Cabel L, Fuerea A, Lacroix L, Baldini C, Martin P, Hollebecque A, Postel-Vinay S, Varga A, Balheda R, Gazzah A, Michot JM, Marabelle A, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, Scoazec JY, Ammari S, André F, Soria JC, Massard C, Verlingue L. Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. Oncotarget 2018;9:9741-50. [PMID: 29515767 DOI: 10.18632/oncotarget.24188] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
54 Magbanua MJM, Rugo HS, Wolf DM, Hauranieh L, Roy R, Pendyala P, Sosa EV, Scott JH, Lee JS, Pitcher B, Hyslop T, Barry WT, Isakoff SJ, Dickler M, Van't Veer L, Park JW. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance). Clin Cancer Res 2018;24:1486-99. [PMID: 29311117 DOI: 10.1158/1078-0432.CCR-17-2312] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
55 Le Du F, Ueno NT, Gonzalez-Angulo AM. Breast Cancer Biomarkers: Utility in Clinical Practice. Curr Breast Cancer Rep 2013;5. [PMID: 24416469 DOI: 10.1007/s12609-013-0125-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
56 Singh A, Sirohi B, Gupta S. Biomarkers in Breast Cancer and the Implications of Their Discordance. Curr Breast Cancer Rep 2013;5:266-74. [DOI: 10.1007/s12609-013-0126-8] [Reference Citation Analysis]
57 Liu F, Wang M, Li H. Role of perfusion parameters on DCE-MRI and ADC values on DWMRI for invasive ductal carcinoma at 3.0 Tesla. World J Surg Oncol 2018;16:239. [PMID: 30577820 DOI: 10.1186/s12957-018-1538-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
58 Criscitiello C, André F, Thompson AM, De Laurentiis M, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, Orsi F, Goldhirsch A, Curigliano G. Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. Breast Cancer Res 2014;16:205. [PMID: 25032257 DOI: 10.1186/bcr3630] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
59 Tang MH, Dahlgren M, Brueffer C, Tjitrowirjo T, Winter C, Chen Y, Olsson E, Wang K, Törngren T, Sjöström M, Grabau D, Bendahl PO, Rydén L, Niméus E, Saal LH, Borg Å, Gruvberger-Saal SK. Remarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencing. Oncotarget 2015;6:37169-84. [PMID: 26439695 DOI: 10.18632/oncotarget.5951] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
60 Jin X, Mu P. Targeting Breast Cancer Metastasis. Breast Cancer (Auckl) 2015;9:23-34. [PMID: 26380552 DOI: 10.4137/BCBCR.S25460] [Cited by in Crossref: 35] [Cited by in F6Publishing: 50] [Article Influence: 5.0] [Reference Citation Analysis]
61 Ieni A, Barresi V, Caltabiano R, Cascone AM, Del Sordo R, Cabibi D, Zeppa P, Lanzafame S, Sidoni A, Franco V, Tuccari G. Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation. Onco Targets Ther 2014;7:1267-72. [PMID: 25050068 DOI: 10.2147/OTT.S65294] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
62 Ross DS, Liu B, Schram AM, Razavi P, Lagana SM, Zhang Y, Scaltriti M, Bromberg JF, Ladanyi M, Hyman DM, Drilon A, Zehir A, Benayed R, Chandarlapaty S, Hechtman JF. Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients. Ann Oncol 2020;31:991-1000. [PMID: 32348852 DOI: 10.1016/j.annonc.2020.04.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
63 Peintinger F, Reitsamer R, Smidt ML, Kühn T, Liedtke C. Lymph Nodes in Breast Cancer - What Can We Learn from Translational Research? Breast Care (Basel) 2018;13:342-7. [PMID: 30498419 DOI: 10.1159/000492435] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Hou Y, Shen R, Chaudhary S, Gao F, Li Z. Correlation of Expression of Breast Biomarkers in Primary and Metastatic Breast Carcinomas: A Single-Institution Experience. Acta Cytol 2016;60:481-9. [PMID: 27681712 DOI: 10.1159/000449400] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
65 Shiino S, Ball G, Syed BM, Kurozumi S, Green AR, Tsuda H, Takayama S, Suto A, Rakha EA. Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis. Breast Cancer Res Treat 2021. [PMID: 34613502 DOI: 10.1007/s10549-021-06390-6] [Reference Citation Analysis]
66 Turashvili G, Brogi E. Tumor Heterogeneity in Breast Cancer. Front Med (Lausanne). 2017;4:227. [PMID: 29276709 DOI: 10.3389/fmed.2017.00227] [Cited by in Crossref: 152] [Cited by in F6Publishing: 134] [Article Influence: 30.4] [Reference Citation Analysis]
67 Abedi-Ardekani B, Vielh P. Is liquid-based cytology the magic bullet for performing molecular techniques? Acta Cytol 2014;58:574-81. [PMID: 25277086 DOI: 10.1159/000366260] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
68 Chen X, Sun L, Cong Y, Zhang T, Lin Q, Meng Q, Pang H, Zhao Y, Li Y, Cai L, Dong X. Baseline staging tests based on molecular subtype is necessary for newly diagnosed breast cancer. J Exp Clin Cancer Res 2014;33:28. [PMID: 24628817 DOI: 10.1186/1756-9966-33-28] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
69 Xu G, Chhangawala S, Cocco E, Razavi P, Cai Y, Otto JE, Ferrando L, Selenica P, Ladewig E, Chan C, Da Cruz Paula A, Witkin M, Cheng Y, Park J, Serna-Tamayo C, Zhao H, Wu F, Sallaku M, Qu X, Zhao A, Collings CK, D'Avino AR, Jhaveri K, Koche R, Levine RL, Reis-Filho JS, Kadoch C, Scaltriti M, Leslie CS, Baselga J, Toska E. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nat Genet 2020;52:198-207. [PMID: 31932695 DOI: 10.1038/s41588-019-0554-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 21.5] [Reference Citation Analysis]
70 Curtit E, Nerich V, Mansi L, Chaigneau L, Cals L, Villanueva C, Bazan F, Montcuquet P, Meneveau N, Perrin S, Algros MP, Pivot X. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Oncologist 2013;18:667-74. [PMID: 23723333 DOI: 10.1634/theoncologist.2012-0350] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 5.6] [Reference Citation Analysis]
71 O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat 2022. [PMID: 35545724 DOI: 10.1007/s10549-022-06602-7] [Reference Citation Analysis]
72 Yu J, Li NL. Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report. World J Clin Cases 2022; 10(17): 5923-5928 [DOI: 10.12998/wjcc.v10.i17.5923] [Reference Citation Analysis]
73 Lim SB, Lim CT, Lim WT. Single-Cell Analysis of Circulating Tumor Cells: Why Heterogeneity Matters. Cancers (Basel) 2019;11:E1595. [PMID: 31635038 DOI: 10.3390/cancers11101595] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
74 Robertson S, Rönnlund C, de Boniface J, Hartman J. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant. Breast Cancer Res Treat 2019;174:795-805. [PMID: 30659433 DOI: 10.1007/s10549-018-05119-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
75 Waclaw B, Bozic I, Pittman ME, Hruban RH, Vogelstein B, Nowak MA. A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity. Nature 2015;525:261-4. [PMID: 26308893 DOI: 10.1038/nature14971] [Cited by in Crossref: 317] [Cited by in F6Publishing: 251] [Article Influence: 45.3] [Reference Citation Analysis]
76 Chen R, Guo S, Yang C, Sun L, Zong B, Li K, Liu L, Tu G, Liu M, Liu S. Although c‑MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER‑positive breast cancer. Int J Oncol 2020;56:932-44. [PMID: 32319562 DOI: 10.3892/ijo.2020.4987] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
77 Nunnery SE, Mayer IA. Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer. Drugs 2020;80:1685-97. [PMID: 32894420 DOI: 10.1007/s40265-020-01394-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
78 Zhao W, Sun L, Dong G, Wang X, Jia Y, Tong Z. Receptor conversion impacts outcomes of different molecular subtypes of primary breast cancer. Ther Adv Med Oncol 2021;13:17588359211012982. [PMID: 33995598 DOI: 10.1177/17588359211012982] [Reference Citation Analysis]
79 Duchnowska R, Sperinde J, Chenna A, Huang W, Weidler JM, Winslow J, Haddad M, Paquet A, Lie Y, Trojanowski T, Mandat T, Kowalczyk A, Czartoryska-Arłukowicz B, Radecka B, Jarosz B, Staszkiewicz R, Kalinka-Warzocha E, Chudzik M, Biernat W, Jassem J. Quantitative HER2 and p95HER2 levels in primary breast cancers and matched brain metastases. Neuro Oncol 2015;17:1241-9. [PMID: 25681308 DOI: 10.1093/neuonc/nov012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
80 Forsare C, Bendahl PO, Moberg E, Levin Tykjær Jørgensen C, Jansson S, Larsson AM, Aaltonen K, Rydén L. Evolution of Estrogen Receptor Status from Primary Tumors to Metastasis and Serially Collected Circulating Tumor Cells. Int J Mol Sci 2020;21:E2885. [PMID: 32326116 DOI: 10.3390/ijms21082885] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Kijanka M, Warnders FJ, El Khattabi M, Lub-de Hooge M, van Dam GM, Ntziachristos V, de Vries L, Oliveira S, van Bergen En Henegouwen PM. Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery. Eur J Nucl Med Mol Imaging 2013;40:1718-29. [PMID: 23778558 DOI: 10.1007/s00259-013-2471-2] [Cited by in Crossref: 76] [Cited by in F6Publishing: 83] [Article Influence: 8.4] [Reference Citation Analysis]
82 Chan A, Morey A, Brown B, Hastrich D, Willsher P, Ingram D. A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease. BMC Cancer 2012;12:555. [PMID: 23176370 DOI: 10.1186/1471-2407-12-555] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
83 McAnena PF, McGuire A, Ramli A, Curran C, Malone C, McLaughlin R, Barry K, Brown JAL, Kerin MJ. Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options. BMC Cancer 2018;18:203. [PMID: 29463223 DOI: 10.1186/s12885-018-4101-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
84 Jones CJ, Subramaniam M, Emch MJ, Bruinsma ES, Ingle JN, Goetz MP, Hawse JR. Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models. Mol Cancer Res 2021;19:1026-39. [PMID: 33627502 DOI: 10.1158/1541-7786.MCR-20-0872] [Reference Citation Analysis]
85 Meng X, Song S, Jiang ZF, Sun B, Wang T, Zhang Sh, Wu Sh. Receptor conversion in metastatic breast cancer: a prognosticator of survival. Oncotarget 2016;7:71887-903. [PMID: 27655689 DOI: 10.18632/oncotarget.12114] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
86 Zeng J, Piscuoglio S, Aggarwal G, Magda J, Friedlander MA, Murray M, Akram M, Reis-Filho JS, Weigelt B, Edelweiss M. Hormone receptor and HER2 assessment in breast carcinoma metastatic to bone: A comparison between FNA cell blocks and decalcified core needle biopsies. Cancer Cytopathol 2020;128:133-45. [PMID: 31883437 DOI: 10.1002/cncy.22226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
87 Lv H, Niu L, Zhang M, Zeng H, Zhao S, Yan M. Diagnostic diversity and heterogeneity of tumors: a real-world study of metastasis re-biopsy in advanced breast cancer. Chin Med J (Engl) 2022. [PMID: 35916549 DOI: 10.1097/CM9.0000000000001969] [Reference Citation Analysis]
88 Kaminska K, Akrap N, Staaf J, Alves CL, Ehinger A, Ebbesson A, Hedenfalk I, Beumers L, Veerla S, Harbst K, Ehmsen S, Borgquist S, Borg Å, Pérez-Fidalgo A, Ditzel HJ, Bosch A, Honeth G. Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer. Breast Cancer Res 2021;23:26. [PMID: 33602273 DOI: 10.1186/s13058-021-01402-1] [Reference Citation Analysis]
89 Stefanovic S, Wirtz R, Deutsch TM, Hartkopf A, Sinn P, Varga Z, Sobottka B, Sotiris L, Taran FA, Domschke C, Hennigs A, Brucker SY, Sohn C, Schuetz F, Schneeweiss A, Wallwiener M. Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry. Oncotarget 2017;8:51416-28. [PMID: 28881657 DOI: 10.18632/oncotarget.18006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
90 Salkeni MA, Hall SJ. Metastatic breast cancer: Endocrine therapy landscape reshaped. Avicenna J Med 2017;7:144-52. [PMID: 29119080 DOI: 10.4103/ajm.AJM_20_17] [Cited by in Crossref: 6] [Article Influence: 1.2] [Reference Citation Analysis]
91 Hadjipanteli A, Doolan P, Kyriacou E, Constantinidou A. Breast Cancer Brain Metastasis: The Potential Role of MRI Beyond Current Clinical Applications. Cancer Manag Res 2020;12:9953-64. [PMID: 33116852 DOI: 10.2147/CMAR.S252801] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Weydandt L, Nel I, Kreklau A, Horn LC, Aktas B. Heterogeneity between Core Needle Biopsy and Synchronous Axillary Lymph Node Metastases in Early Breast Cancer Patients-A Comparison of HER2, Estrogen and Progesterone Receptor Expression Profiles during Primary Treatment Regime. Cancers (Basel) 2022;14:1863. [PMID: 35454772 DOI: 10.3390/cancers14081863] [Reference Citation Analysis]
93 Miao H, Sun Y, Jin Y, Hu X, Song S, Zhang J. Application of a Novel 68Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients. Front Oncol 2022;12:894767. [PMID: 35712499 DOI: 10.3389/fonc.2022.894767] [Reference Citation Analysis]
94 Zhu YY, Si W, Ji TF, Guo XQ, Hu Y, Yang JL. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients. Tumour Biol 2016;37:7675-84. [PMID: 26687919 DOI: 10.1007/s13277-015-4649-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
95 Edman Kessler L, Sigfridsson J, Hatzidaki D, Bergh J, Foukakis T, Georgoulias V, Matikas A. Chemotherapy use near the end-of-life in patients with metastatic breast cancer. Breast Cancer Res Treat 2020;181:645-51. [PMID: 32383058 DOI: 10.1007/s10549-020-05663-w] [Reference Citation Analysis]
96 de Gramont A, Watson S, Ellis LM, Rodón J, Tabernero J, de Gramont A, Hamilton SR. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol 2015;12:197-212. [PMID: 25421275 DOI: 10.1038/nrclinonc.2014.202] [Cited by in Crossref: 126] [Cited by in F6Publishing: 98] [Article Influence: 15.8] [Reference Citation Analysis]
97 Falck AK, Fernö M, Bendahl PO, Rydén L. St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases--aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial. BMC Cancer 2013;13:558. [PMID: 24274821 DOI: 10.1186/1471-2407-13-558] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
98 Goldstein R, Sosabowski J, Livanos M, Leyton J, Vigor K, Bhavsar G, Nagy-Davidescu G, Rashid M, Miranda E, Yeung J, Tolner B, Plückthun A, Mather S, Meyer T, Chester K. Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging. Eur J Nucl Med Mol Imaging 2015;42:288-301. [PMID: 25391547 DOI: 10.1007/s00259-014-2940-2] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
99 Chen YY, Li CF, Yeh CH, Chang MS, Hsing CH. Interleukin-19 in breast cancer. Clin Dev Immunol 2013;2013:294320. [PMID: 23710200 DOI: 10.1155/2013/294320] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
100 Kjällquist U, Erlandsson R, Tobin NP, Alkodsi A, Ullah I, Stålhammar G, Karlsson E, Hatschek T, Hartman J, Linnarsson S, Bergh J. Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs). BMC Cancer 2018;18:174. [PMID: 29433456 DOI: 10.1186/s12885-018-4021-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
101 Aaltonen KE, Novosadová V, Bendahl PO, Graffman C, Larsson AM, Rydén L. Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy. Oncotarget 2017;8:45544-65. [PMID: 28489591 DOI: 10.18632/oncotarget.17271] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
102 Angajala A, Mothershed E, Davis MB, Tripathi S, He Q, Bedi D, Dean-Colomb W, Yates C. Quadruple Negative Breast Cancers (QNBC) Demonstrate Subtype Consistency among Primary and Recurrent or Metastatic Breast Cancer. Transl Oncol 2019;12:493-501. [PMID: 30594038 DOI: 10.1016/j.tranon.2018.11.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
103 Tuxen MK, Cold S, Tange UB, Balslev E, Nielsen DL. Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer. Acta Oncol 2014;53:1440-5. [PMID: 24991893 DOI: 10.3109/0284186X.2014.921727] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
104 Walter V, Fischer C, Deutsch TM, Ersing C, Nees J, Schütz F, Fremd C, Grischke EM, Sinn P, Brucker SY, Schneeweiss A, Hartkopf AD, Wallwiener M. Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer. Breast Cancer Res Treat 2020;183:137-44. [PMID: 32613540 DOI: 10.1007/s10549-020-05746-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
105 Shinden Y, Sugimachi K, Tanaka F, Fujiyoshi K, Kijima Y, Natsugoe S, Mimori K. Clinicopathological characteristics of disseminated carcinomatosis of the bone marrow in breast cancer patients. Mol Clin Oncol 2018;8:93-8. [PMID: 29423222 DOI: 10.3892/mco.2017.1502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
106 Castaño Z, Marsh T, Tadipatri R, Kuznetsov HS, Al-Shahrour F, Paktinat M, Greene-Colozzi A, Nilsson B, Richardson AL, McAllister SS. Stromal EGF and igf-I together modulate plasticity of disseminated triple-negative breast tumors. Cancer Discov 2013;3:922-35. [PMID: 23689072 DOI: 10.1158/2159-8290.CD-13-0041] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
107 Ding Y, Liu Y, Lee DK, Tong Z, Yu X, Li Y, Xu Y, Lanz RB, O'Malley BW, Xu J. Cell lineage tracing links ERα loss in Erbb2-positive breast cancers to the arising of a highly aggressive breast cancer subtype. Proc Natl Acad Sci U S A 2021;118:e2100673118. [PMID: 34006643 DOI: 10.1073/pnas.2100673118] [Reference Citation Analysis]
108 Lindström LS, Yau C, Czene K, Thompson CK, Hoadley KA, Van't Veer LJ, Balassanian R, Bishop JW, Carpenter PM, Chen YY, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y, Nordenskjöld B, Stål O, Benz CC, Fornander T, Borowsky AD, Esserman LJ; STO Trialists Group. Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer. J Natl Cancer Inst 2018;110:726-33. [PMID: 29361175 DOI: 10.1093/jnci/djx270] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
109 Eroglu Z, Tagawa T, Somlo G. Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. Oncologist 2014;19:135-50. [PMID: 24436312 DOI: 10.1634/theoncologist.2013-0283] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
110 Sauter ER. Reliable Biomarkers to Identify New and Recurrent Cancer. Eur J Breast Health 2017;13:162-7. [PMID: 29082372 DOI: 10.5152/ejbh.2017.3635] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
111 Haddad TC, D'Assoro A, Suman V, Opyrchal M, Peethambaram P, Liu MC, Goetz MP, Ingle JN. Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer. Breast Cancer Res Treat 2018;168:639-47. [PMID: 29289986 DOI: 10.1007/s10549-017-4616-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
112 Ge LP, Liu XY, Xiao Y, Gou ZC, Zhao S, Jiang YZ, Di GH. Clinicopathological characteristics and treatment outcomes of occult breast cancer: a SEER population-based study. Cancer Manag Res. 2018;10:4381-4391. [PMID: 30349371 DOI: 10.2147/cmar.s169019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
113 Stefanovic S, Deutsch TM, Wirtz R, Hartkopf A, Sinn P, Kohler M, Hofmann J, Bankovic S, Vassilev K, Sütterlin M, Schneeweiss A, Wallwiener M. Impact of mRNA-Assessed Molecular Subtype Conversion, Intact and Apoptotic Circulating Tumor Cells on Survival of Metastatic Breast Cancer Patients: Proof of Principle. Diagnostics (Basel) 2020;10:E369. [PMID: 32512707 DOI: 10.3390/diagnostics10060369] [Reference Citation Analysis]
114 Mandó P, Rizzo M, de la Puente CP, Maino M, Ponce C, Pombo MT, Amat M, Costanzo MV, Nervo A, Nadal J, Fabiano V, Loza J, Loza CM, Colo F, Reinaldo C. High Histologic Grade and High Ki-67 Expression Predict Phenotypic Alterations in Node Metastasis in Primary Breast Cancers. J Breast Cancer 2017;20:170-5. [PMID: 28690653 DOI: 10.4048/jbc.2017.20.2.170] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
115 Grinda T, Joyon N, Lusque A, Lefèvre S, Arnould L, Penault-Llorca F, Macgrogan G, Treilleux I, Vincent-Salomon A, Haudebourg J, Maran-Gonzalez A, Charafe-Jauffret E, Courtinard C, Franchet C, Verriele V, Brain E, Tas P, Blanc-Fournier C, Leroux A, Loussouarn D, Berghian A, Brabencova E, Ghnassia JP, Scoazec JY, Delaloge S, Filleron T, Lacroix-Triki M. Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort. NPJ Breast Cancer 2021;7:41. [PMID: 33863896 DOI: 10.1038/s41523-021-00252-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
116 Dalag L, Fergus JK, Zangan SM. Lung and Abdominal Biopsies in the Age of Precision Medicine. Semin Intervent Radiol 2019;36:255-63. [PMID: 31435134 DOI: 10.1055/s-0039-1693121] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
117 Ditsch N, Schmidt M. Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer. Geburtshilfe Frauenheilkd 2019;79:1328-35. [PMID: 31875862 DOI: 10.1055/a-1037-5205] [Reference Citation Analysis]
118 Vazquez Rodriguez G, Abrahamsson A, Jensen LDE, Dabrosin C. Adipocytes Promote Early Steps of Breast Cancer Cell Dissemination via Interleukin-8. Front Immunol 2018;9:1767. [PMID: 30105032 DOI: 10.3389/fimmu.2018.01767] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
119 Edman Kessler L, Wiklander O, Hamberg E, Bergh J, Foukakis T, Matikas A. Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience. Acta Oncol 2020;59:1382-7. [PMID: 32783667 DOI: 10.1080/0284186X.2020.1804613] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
120 Jeselsohn R, Cornwell M, Pun M, Buchwalter G, Nguyen M, Bango C, Huang Y, Kuang Y, Paweletz C, Fu X, Nardone A, De Angelis C, Detre S, Dodson A, Mohammed H, Carroll JS, Bowden M, Rao P, Long HW, Li F, Dowsett M, Schiff R, Brown M. Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. Proc Natl Acad Sci U S A 2017;114:E4482-91. [PMID: 28507152 DOI: 10.1073/pnas.1620993114] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 10.6] [Reference Citation Analysis]
121 Pantel AR, Mankoff DA. Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers. Cancer Lett 2017;387:25-31. [PMID: 27195912 DOI: 10.1016/j.canlet.2016.05.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
122 Guo Q, Spasic M, Maynard AG, Goreczny GJ, Bizuayehu A, Olive JF, van Galen P, McAllister SS. Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research. Nat Commun 2022;13:3837. [PMID: 35788590 DOI: 10.1038/s41467-022-31536-5] [Reference Citation Analysis]
123 Li Y, Qin J, Wu J, Dai X, Xu J. High expression of OSR1 as a predictive biomarker for poor prognosis and lymph node metastasis in breast cancer. Breast Cancer Res Treat 2020;182:35-46. [PMID: 32424721 DOI: 10.1007/s10549-020-05671-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
124 López-Cortés A, Cabrera-Andrade A, Oña-Cisneros F, Echeverría C, Rosales F, Ortiz M, Tejera E, Paz-Y-Miño C. Breast Cancer Risk Associated with Genotype Polymorphisms of the Aurora Kinase a Gene (AURKA): a Case-Control Study in a High Altitude Ecuadorian Mestizo Population. Pathol Oncol Res 2018;24:457-65. [PMID: 28647900 DOI: 10.1007/s12253-017-0267-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
125 Müller V, Banys-Paluchowski M, Friedl TWP, Fasching PA, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, Huober J, Rübner M, Hoffmann O, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T; DETECT study group. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open 2021;6:100299. [PMID: 34839105 DOI: 10.1016/j.esmoop.2021.100299] [Reference Citation Analysis]
126 Markiewicz A, Ahrends T, Wełnicka-Jaśkiewicz M, Seroczyńska B, Skokowski J, Jaśkiewicz J, Szade J, Biernat W, Zaczek AJ. Expression of epithelial to mesenchymal transition-related markers in lymph node metastases as a surrogate for primary tumor metastatic potential in breast cancer. J Transl Med 2012;10:226. [PMID: 23157797 DOI: 10.1186/1479-5876-10-226] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.6] [Reference Citation Analysis]
127 Liu Z, Zhang J, Xu J, Yang H, Li X, Hou Y, Zhao Y, Xue M, Wang B, Yu N, Yu S, Niu G, Wu G, Li X, Wang H, Zhu J, Zhuang T. RNF168 facilitates oestrogen receptor ɑ transcription and drives breast cancer proliferation. J Cell Mol Med 2018;22:4161-70. [PMID: 29974997 DOI: 10.1111/jcmm.13694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
128 Frithiof H, Welinder C, Larsson AM, Rydén L, Aaltonen K. A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation. J Transl Med 2015;13:126. [PMID: 25896421 DOI: 10.1186/s12967-015-0493-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
129 Foukakis T, Lövrot J, Matikas A, Zerdes I, Lorent J, Tobin N, Suzuki C, Brage SE, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Fernö M, Skoog L, Bergh J, Hatschek T. Immune gene expression and response to chemotherapy in advanced breast cancer. Br J Cancer 2018;118:480-8. [PMID: 29370583 DOI: 10.1038/bjc.2017.446] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
130 Tobin NP, Harrell JC, Lövrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Walz T, Fernö M, Perou CM, Bergh J, Hatschek T, Lindström LS; TEX Trialists Group. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Ann Oncol 2015;26:81-8. [PMID: 25361981 DOI: 10.1093/annonc/mdu498] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 5.8] [Reference Citation Analysis]
131 Harbeck N, Wuerstlein R. Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations. Drugs 2013;73:1665-80. [PMID: 24127221 DOI: 10.1007/s40265-013-0118-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
132 Vantaggiato C, Tocchetti M, Cappelletti V, Gurtner A, Villa A, Daidone MG, Piaggio G, Maggi A, Ciana P. Cell cycle dependent oscillatory expression of estrogen receptor-α links Pol II elongation to neoplastic transformation. Proc Natl Acad Sci U S A 2014;111:9561-6. [PMID: 24979764 DOI: 10.1073/pnas.1321750111] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
133 Allison KH. Molecular pathology of breast cancer: what a pathologist needs to know. Am J Clin Pathol 2012;138:770-80. [PMID: 23161709 DOI: 10.1309/AJCPIV9IQ1MRQMOO] [Cited by in Crossref: 59] [Cited by in F6Publishing: 29] [Article Influence: 5.9] [Reference Citation Analysis]
134 AlFakeeh A, Brezden-Masley C. Overcoming endocrine resistance in hormone receptor-positive breast cancer. Curr Oncol 2018;25:S18-27. [PMID: 29910644 DOI: 10.3747/co.25.3752] [Cited by in Crossref: 47] [Cited by in F6Publishing: 32] [Article Influence: 11.8] [Reference Citation Analysis]
135 Vazquez Rodriguez G, Abrahamsson A, Turkina MV, Dabrosin C. Lysine in Combination With Estradiol Promote Dissemination of Estrogen Receptor Positive Breast Cancer via Upregulation of U2AF1 and RPN2 Proteins. Front Oncol 2020;10:598684. [PMID: 33330095 DOI: 10.3389/fonc.2020.598684] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
136 Møller EK, Kumar P, Voet T, Peterson A, Van Loo P, Mathiesen RR, Fjelldal R, Grundstad J, Borgen E, Baumbusch LO, Naume B, Børresen-Dale AL, White KP, Nord S, Kristensen VN. Next-generation sequencing of disseminated tumor cells. Front Oncol 2013;3:320. [PMID: 24427740 DOI: 10.3389/fonc.2013.00320] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
137 Miyamoto DT, Ting DT, Toner M, Maheswaran S, Haber DA. Single-Cell Analysis of Circulating Tumor Cells as a Window into Tumor Heterogeneity. Cold Spring Harb Symp Quant Biol 2016;81:269-74. [PMID: 28389596 DOI: 10.1101/sqb.2016.81.031120] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
138 Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, Hicks DG, Hill EG, Liu MC, Lucas W, Mayer IA, Mennel RG, Symmans WF, Hayes DF, Harris LN. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2015;33:2695-704. [PMID: 26195705 DOI: 10.1200/JCO.2015.61.1459] [Cited by in Crossref: 169] [Cited by in F6Publishing: 91] [Article Influence: 24.1] [Reference Citation Analysis]
139 Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, Hwang S, Berry DA, Kinzler KW, Black WC, Bissell M, Parnes H, Srivastava S. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 2014;15:e234-e242. [PMID: 24807866 DOI: 10.1016/s1470-2045(13)70598-9] [Cited by in Crossref: 291] [Cited by in F6Publishing: 129] [Article Influence: 36.4] [Reference Citation Analysis]
140 Mou H, Wang Z, Zhang W, Li G, Zhou H, Yinwang E, Wang F, Sun H, Xue Y, Wang Z, Chen T, Chai X, Qu H, Lin P, Teng W, Li B, Ye Z. Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis Surgeries. Front Oncol 2021;11:693689. [PMID: 34604031 DOI: 10.3389/fonc.2021.693689] [Reference Citation Analysis]
141 Patel SH, Saito YD, Li Z, Ramaswamy B, Stiff A, Kassem M, Wesolowski R. A solitary brain metastasis as the only site of recurrence of HR positive, HER2 negative breast cancer: a case report and review of the literature. J Med Case Rep 2021;15:4. [PMID: 33407851 DOI: 10.1186/s13256-020-02615-2] [Reference Citation Analysis]
142 Hartkopf AD, Grischke EM, Brucker SY. Endocrine-Resistant Breast Cancer: Mechanisms and Treatment. Breast Care (Basel) 2020;15:347-54. [PMID: 32982644 DOI: 10.1159/000508675] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Harbeck N, Scharl A, Thomssen C, Müller V. AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013. Breast Care (Basel) 2013;8:181-5. [PMID: 24415967 DOI: 10.1159/000353590] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
144 Xia X, He J, Liu B, Shao Z, Xu Q, Hu T, Yu C, Liu X, Liao Y, Liu N, Huang H. Targeting ERα degradation by L-Tetrahydropalmatine provides a novel strategy for breast cancer treatment. Int J Biol Sci 2020;16:2192-204. [PMID: 32549765 DOI: 10.7150/ijbs.44005] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
145 Yao ZX, Lu LJ, Wang RJ, Jin LB, Liu SC, Li HY, Ren GS, Wu KN, Wang DL, Kong LQ. Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis. Med Oncol 2014;31:798. [PMID: 24307349 DOI: 10.1007/s12032-013-0798-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
146 Mehraj U, Mushtaq U, Mir MA, Saleem A, Macha MA, Lone MN, Hamid A, Zargar MA, Ahmad SM, Wani NA. Chemokines in Triple-Negative Breast Cancer Heterogeneity: New Challenges for Clinical Implications. Semin Cancer Biol 2022:S1044-579X(22)00064-5. [PMID: 35278636 DOI: 10.1016/j.semcancer.2022.03.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
147 Milosevic J, Klinge J, Borg AL, Foukakis T, Bergh J, Tobin NP. Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies. BMC Cancer 2013;13:473. [PMID: 24119434 DOI: 10.1186/1471-2407-13-473] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
148 Paik HJ, Lee SK, Ryu JM, Park S, Kim I, Bae SY, Yu J, Lee JE, Kim SW, Nam SJ. Conditional disease-free survival among patients with breast cancer. Medicine (Baltimore) 2017;96:e5746. [PMID: 28072715 DOI: 10.1097/MD.0000000000005746] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
149 Kimbung S, Kovács A, Danielsson A, Bendahl PO, Lövgren K, Frostvik Stolt M, Tobin NP, Lindström L, Bergh J, Einbeigi Z, Fernö M, Hatschek T, Hedenfalk I. Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications. Oncotarget 2015;6:33306-18. [PMID: 26375671 DOI: 10.18632/oncotarget.5089] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
150 Min Y, Feng Y, Luo H, Hu D, Wei X, He D, Yin G, Fan S. Identifying and Validating of an Autophagy-Related Gene Signature for the Prediction of Early Relapse in Breast Cancer. Front Endocrinol (Lausanne) 2022;13:824362. [PMID: 35250881 DOI: 10.3389/fendo.2022.824362] [Reference Citation Analysis]
151 Sighoko D, Liu J, Hou N, Gustafson P, Huo D. Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification? Oncologist 2014;19:592-601. [PMID: 24807915 DOI: 10.1634/theoncologist.2013-0427] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
152 Sarink D, Schock H, Johnson T, Chang-Claude J, Overvad K, Olsen A, Tjønneland A, Arveux P, Fournier A, Kvaskoff M, Boeing H, Karakatsani A, Trichopoulou A, La Vecchia C, Masala G, Agnoli C, Panico S, Tumino R, Sacerdote C, van Gils CH, Peeters PHM, Weiderpass E, Agudo A, Rodríguez-Barranco M, Huerta JM, Ardanaz E, Gil L, Kaw KT, Schmidt JA, Dossus L, His M, Aune D, Riboli E, Kaaks R, Fortner RT. Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort. BMC Cancer 2018;18:1010. [PMID: 30348163 DOI: 10.1186/s12885-018-4887-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
153 Liu S, Sun X, Xu X, Lin F. Comparison of Endocrine Therapies in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer: A Network Meta-Analysis. J Breast Cancer 2020;23:460-83. [PMID: 33154823 DOI: 10.4048/jbc.2020.23.e55] [Reference Citation Analysis]
154 Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature 2013;501:355-64. [PMID: 24048068 DOI: 10.1038/nature12627] [Cited by in Crossref: 700] [Cited by in F6Publishing: 622] [Article Influence: 77.8] [Reference Citation Analysis]
155 Kotecha R, Tonse R, Rubens M, McDermott MW, Odia Y, Appel H, Mehta MP. Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance. Neurooncol Adv 2021;3:vdab010. [PMID: 33898990 DOI: 10.1093/noajnl/vdab010] [Reference Citation Analysis]
156 Zhu J, Zhao C, Kharman-Biz A, Zhuang T, Jonsson P, Liang N, Williams C, Lin CY, Qiao Y, Zendehdel K, Strömblad S, Treuter E, Dahlman-Wright K. The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor α and modulates estrogen-stimulated breast cancer cell proliferation. Oncogene 2014;33:4340-51. [PMID: 24441041 DOI: 10.1038/onc.2013.573] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 6.1] [Reference Citation Analysis]
157 Ostman A. The tumor microenvironment controls drug sensitivity. Nat Med 2012;18:1332-4. [PMID: 22961158 DOI: 10.1038/nm.2938] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 8.1] [Reference Citation Analysis]
158 Pereira PMR, Sharma SK, Carter LM, Edwards KJ, Pourat J, Ragupathi A, Janjigian YY, Durack JC, Lewis JS. Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nat Commun 2018;9:5137. [PMID: 30510281 DOI: 10.1038/s41467-018-07608-w] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 10.3] [Reference Citation Analysis]
159 Lu Y, Tong Y, Chen X, Shen K. Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients. Front Oncol 2021;11:638619. [PMID: 34277399 DOI: 10.3389/fonc.2021.638619] [Reference Citation Analysis]
160 Georgescu R, Boros M, Moncea D, Bauer O, Coros MF, Oprea A, Moldovan C, Podoleanu C, Stolnicu S. Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic Decision. Appl Immunohistochem Mol Morphol 2018;26:533-8. [PMID: 28099174 DOI: 10.1097/PAI.0000000000000483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
161 Karthik GM, Rantalainen M, Stålhammar G, Lövrot J, Ullah I, Alkodsi A, Ma R, Wedlund L, Lindberg J, Frisell J, Bergh J, Hartman J. Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling. BMC Cancer 2017;17:802. [PMID: 29187174 DOI: 10.1186/s12885-017-3815-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
162 Jauw YW, Menke-van der Houven van Oordt CW, Hoekstra OS, Hendrikse NH, Vugts DJ, Zijlstra JM, Huisman MC, van Dongen GA. Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials? Front Pharmacol 2016;7:131. [PMID: 27252651 DOI: 10.3389/fphar.2016.00131] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 17.2] [Reference Citation Analysis]
163 Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Sperduto W, Lou E, Everett A, Boggs DH, Masucci L, Roberge D, Remick J, Plichta K, Buatti JM, Jain S, Gaspar LE, Wu CC, Wang TJC, Bryant J, Chuong M, Yu J, Chiang V, Nakano T, Aoyama H, Mehta MP. Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Neuro Oncol 2020;22:1359-67. [PMID: 32034917 DOI: 10.1093/neuonc/noaa025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
164 Ding Y, Ding K, Qian H, Yu X, Zou D, Yang H, Mo W, He X, Zhang F, Qin C, Zheng Y, Ding X. Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer. PLoS One 2020;15:e0231895. [PMID: 32298374 DOI: 10.1371/journal.pone.0231895] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
165 Krieger N. History, biology, and health inequities: emergent embodied phenotypes and the illustrative case of the breast cancer estrogen receptor. Am J Public Health 2013;103:22-7. [PMID: 23153126 DOI: 10.2105/AJPH.2012.300967] [Cited by in Crossref: 28] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
166 Freedman OC, Fletcher GG, Gandhi S, Mates M, Dent SF, Trudeau ME, Eisen A. Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol. 2015;22:S95-S113. [PMID: 25848344 DOI: 10.3747/co.22.2326] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
167 Sarangi S, Mosulpuria K, Higgins MJ, Bardia A. The Evolving Role of Circulating Tumor Cells in the Personalized Management of Breast Cancer: from Enumeration to Molecular Characterization. Curr Breast Cancer Rep 2014;6:146-53. [PMID: 25431637 DOI: 10.1007/s12609-014-0149-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
168 Velikyan I. (Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer. Pharmaceuticals (Basel) 2020;13:E39. [PMID: 32151049 DOI: 10.3390/ph13030039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
169 Reddy TP, Choi DS, Anselme AC, Qian W, Chen W, Lantto J, Horak ID, Kragh M, Chang JC, Rosato RR. Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs. Breast Cancer Res 2020;22:48. [PMID: 32414394 DOI: 10.1186/s13058-020-01280-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
170 Gogia A, Deo SVS, Sharma D, Phulia RK, Thulkar S, Malik PS, Mathur S. Discordance in Biomarker Expression in Breast Cancer After Metastasis: Single Center Experience in India. J Glob Oncol 2019;5:1-8. [PMID: 30951390 DOI: 10.1200/JGO.18.00184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
171 Cartaxo AL, Estrada MF, Domenici G, Roque R, Silva F, Gualda EJ, Loza-Alvarez P, Sflomos G, Brisken C, Alves PM, André S, Brito C. A novel culture method that sustains ERα signaling in human breast cancer tissue microstructures. J Exp Clin Cancer Res 2020;39:161. [PMID: 32807212 DOI: 10.1186/s13046-020-01653-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
172 Caparica R, Mak MP, Rocha CH, Velho PHI, Viana P, Moura MRL, Menezes MR, Amato MBP, Feher O. Pulmonary Nodules in Patients With Nonpulmonary Cancer: Not Always Metastases. J Glob Oncol 2016;2:138-44. [PMID: 28717693 DOI: 10.1200/JGO.2015.002089] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
173 Sörensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, Orlova A, Sandström M, Lubberink M, Olofsson H, Carlsson J, Lindman H. Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT. Theranostics 2016;6:262-71. [PMID: 26877784 DOI: 10.7150/thno.13502] [Cited by in Crossref: 138] [Cited by in F6Publishing: 117] [Article Influence: 23.0] [Reference Citation Analysis]
174 Braun M, Markiewicz A, Kordek R, Sądej R, Romańska H. Profiling of Invasive Breast Carcinoma Circulating Tumour Cells-Are We Ready for the 'Liquid' Revolution? Cancers (Basel) 2019;11:E143. [PMID: 30691008 DOI: 10.3390/cancers11020143] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
175 Sakai H, Tsurutani J, Iwasa T, Komoike Y, Sakai K, Nishio K, Nakagawa K. HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. Breast Cancer 2018;25:605-13. [PMID: 29700710 DOI: 10.1007/s12282-018-0861-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
176 Strand F, Humphreys K, Holm J, Eriksson M, Törnberg S, Hall P, Azavedo E, Czene K. Long-term prognostic implications of risk factors associated with tumor size: a case study of women regularly attending screening. Breast Cancer Res 2018;20:31. [PMID: 29669579 DOI: 10.1186/s13058-018-0962-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
177 Yang YF, Liao YY, Yang M, Peng NF, Xie SR, Xie YF. Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients. Med Oncol 2014;31:214. [PMID: 25216864 DOI: 10.1007/s12032-014-0214-2] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.1] [Reference Citation Analysis]
178 Aktas B, Kasimir-Bauer S, Müller V, Janni W, Fehm T, Wallwiener D, Pantel K, Tewes M; DETECT Study Group. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. BMC Cancer 2016;16:522. [PMID: 27456970 DOI: 10.1186/s12885-016-2587-4] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 7.3] [Reference Citation Analysis]
179 Pritchard KI, Gelmon KA, Rayson D, Provencher L, Webster M, McLeod D, Verma S. Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement. Curr Oncol 2013;20:48-61. [PMID: 23443928 DOI: 10.3747/co.20.1316] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
180 Winnard PT Jr, Vesuna F, Muthukumar S, Raman V. Divergent organ-specific isogenic metastatic cell lines identified using multi-omics exhibit differential drug sensitivity. PLoS One 2020;15:e0242384. [PMID: 33196681 DOI: 10.1371/journal.pone.0242384] [Reference Citation Analysis]
181 Falato C, Tobin NP, Lorent J, Lindström LS, Bergh J, Foukakis T. Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse. Mol Oncol 2016;10:517-25. [PMID: 26651914 DOI: 10.1016/j.molonc.2015.11.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
182 Jørgensen CL, Bjerre C, Ejlertsen B, Bjerre KD, Balslev E, Bartels A, Brünner N, Nielsen DL. TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group. BMC Cancer 2014;14:360. [PMID: 24884504 DOI: 10.1186/1471-2407-14-360] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
183 Wang L, Hong Y, Ma J, Han M, Zhang S, Shan B, Liu Y. Combination of pegylated liposomal doxorubicin and docetaxel as neoadjuvant therapy for breast cancer with axillary lymph node metastasis. J Int Med Res 2020;48:300060520944310. [PMID: 32776809 DOI: 10.1177/0300060520944310] [Reference Citation Analysis]